Eric Benevich S.'s most recent trade in Neurocrine Biosciences, Inc. was a trade of 36,287 Stock Option done . Disclosure was reported to the exchange on Feb. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 36,287 | 36,287 | - | - | Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 16,613 | 72,153 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.12 per share. | 12 Feb 2026 | 8,963 | 63,190 (0%) | 0% | 124.1 | 1,112,488 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 6,365 | 6,365 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 2,083 | 2,083 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 2,083 | 56,664 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 2,005 | 6,017 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 2,005 | 54,760 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 1,961 | 3,924 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 1,961 | 55,639 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.12 per share. | 12 Feb 2026 | 1,124 | 55,540 (0%) | 0% | 124.1 | 139,511 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.10 per share. | 12 Feb 2026 | 1,082 | 53,678 (0%) | 0% | 123.1 | 133,194 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.12 per share. | 12 Feb 2026 | 1,058 | 54,581 (0%) | 0% | 124.1 | 131,319 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 2,294 | 54,047 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 2,294 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 136.06 per share. | 31 Jan 2026 | 1,292 | 52,755 (0%) | 0% | 136.1 | 175,790 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.99 per share. | 28 Nov 2025 | 12,830 | 57,723 (0%) | 0% | 36.0 | 461,752 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 12,830 | 0 | - | - | Incentive Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 5,970 | 6,860 | - | - | Incentive Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 151.74 per share. | 28 Nov 2025 | 5,970 | 44,893 (0%) | 0% | 151.7 | 905,881 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.99 per share. | 28 Nov 2025 | 5,970 | 50,863 (0%) | 0% | 36.0 | 214,860 | Common Stock |
| Atyr Pharma Inc | Benevich S. Eric | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 42,805 | 42,805 | - | - | Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 8,022 | 8,022 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,083 | 44,882 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,083 | 4,166 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,961 | 5,885 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,961 | 45,745 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 116.74 per share. | 12 Feb 2025 | 1,098 | 43,784 (0%) | 0% | 116.7 | 128,183 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 116.71 per share. | 12 Feb 2025 | 1,056 | 44,689 (0%) | 0% | 116.7 | 123,245 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 1,860 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 1,860 | 43,779 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 118.31 per share. | 08 Feb 2025 | 980 | 42,799 (0%) | 0% | 118.3 | 115,940 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,294 | 43,126 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,294 | 2,294 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 152.94 per share. | 31 Jan 2025 | 1,207 | 41,919 (0%) | 0% | 152.9 | 184,599 | Common Stock |
| Atyr Pharma Inc | Benevich S. Eric | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 12,587 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 133.36 per share. | 15 Apr 2024 | 12,587 | 40,778 (0%) | 0% | 133.4 | 1,678,660 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.05 per share. | 15 Apr 2024 | 12,587 | 53,365 (0%) | 0% | 81.0 | 1,020,176 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.49 per share. | 15 Apr 2024 | 7,231 | 48,009 (0%) | 0% | 81.5 | 589,254 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 7,231 | 26,292 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 133.36 per share. | 15 Apr 2024 | 7,231 | 40,778 (0%) | 0% | 133.4 | 964,359 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 69,521 | 12,587 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 139.38 per share. | 14 Mar 2024 | 69,521 | 40,778 (0%) | 0% | 139.4 | 9,689,761 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.05 per share. | 14 Mar 2024 | 69,521 | 110,299 (0%) | 0% | 81.0 | 5,634,677 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 14 Mar 2024 | 5,479 | 46,257 (0%) | 0% | 79.0 | 432,951 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 5,479 | 33,881 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 139.38 per share. | 14 Mar 2024 | 5,479 | 40,778 (0%) | 0% | 139.4 | 763,657 | Common Stock |
| Neurocrine Biosciences Inc | S. Benevich Eric | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.24 per share. | 28 Feb 2024 | 53,143 | 93,759 (0%) | 0% | 43.2 | 2,297,903 | Common Stock |
| Neurocrine Biosciences Inc | Benevich S. Eric | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 53,143 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | S. Eric Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 134.69 per share. | 28 Feb 2024 | 53,143 | 40,616 (0%) | 0% | 134.7 | 7,157,730 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 21,857 | 39,360 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric Benevich S. | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 134.69 per share. | 28 Feb 2024 | 21,857 | 40,616 (0%) | 0% | 134.7 | 2,943,878 | Common Stock |
| Neurocrine Biosciences Inc | Eric Benevich S. | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 28 Feb 2024 | 21,857 | 62,473 (0%) | 0% | 79.0 | 1,727,140 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 39,426 | 39,426 | - | - | Stock Option | |
| Neurocrine Biosciences Inc | S. Benevich Eric | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 7,846 | 7,846 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Benevich Eric S. | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 133.01 per share. | 13 Feb 2024 | 1,098 | 40,616 (0%) | 0% | 133.0 | 146,050 | Common Stock |
| Neurocrine Biosciences Inc | Eric Benevich S. | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 142.12 per share. | 06 Feb 2024 | 1,280 | 38,751 (0%) | 0% | 142.1 | 181,910 | Common Stock |
| Neurocrine Biosciences Inc | Benevich Eric S. | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 134.19 per share. | 06 Feb 2024 | 980 | 39,631 (0%) | 0% | 134.2 | 131,509 | Common Stock |
| Neurocrine Biosciences Inc | Eric Benevich S. | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 140.78 per share. | 31 Jan 2024 | 1,207 | 37,601 (0%) | 0% | 140.8 | 169,927 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 107.40 per share. | 21 Aug 2023 | 1,600 | 36,436 (0%) | 0% | 107.4 | 171,836 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 51,782 | 51,782 | - | - | Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 8,332 | 8,332 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 102.42 per share. | 06 Feb 2023 | 15,360 | 33,501 (0%) | 0% | 102.4 | 1,573,225 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 102.29 per share. | 06 Feb 2023 | 2,030 | 19,705 (0%) | 0% | 102.3 | 207,643 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 105.63 per share. | 06 Feb 2023 | 1,280 | 17,879 (0%) | 0% | 105.6 | 135,201 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 104.12 per share. | 06 Feb 2023 | 980 | 34,381 (0%) | 0% | 104.1 | 102,036 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 109.95 per share. | 31 Jan 2023 | 1,207 | 16,729 (0%) | 0% | 110.0 | 132,710 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.00 per share. | 06 Jan 2023 | 400 | 15,643 (0%) | 0% | 125 | 50,000 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 400 | 53,143 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.24 per share. | 06 Jan 2023 | 400 | 16,043 (0%) | 0% | 43.2 | 17,296 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.90 per share. | 30 Nov 2022 | 22,162 | 15,643 (0%) | 0% | 125.9 | 2,790,233 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 30 Nov 2022 | 22,162 | 37,805 (0%) | 0% | 41.8 | 925,928 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2022 | 22,162 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2022 | 20,063 | 53,543 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.90 per share. | 30 Nov 2022 | 20,063 | 15,643 (0%) | 0% | 125.9 | 2,525,966 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.24 per share. | 30 Nov 2022 | 20,063 | 35,706 (0%) | 0% | 43.2 | 867,524 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2022 | 7,775 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.90 per share. | 30 Nov 2022 | 7,775 | 15,643 (0%) | 0% | 125.9 | 978,886 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.99 per share. | 30 Nov 2022 | 7,775 | 23,418 (0%) | 0% | 36.0 | 279,822 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.33 per share. | 08 Nov 2022 | 24,593 | 15,643 (0%) | 0% | 125.3 | 3,082,319 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2022 | 24,593 | 22,262 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 08 Nov 2022 | 24,593 | 40,236 (0%) | 0% | 41.8 | 1,027,496 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2022 | 100 | 22,162 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.36 per share. | 08 Nov 2022 | 100 | 15,643 (0%) | 0% | 125.4 | 12,536 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 08 Nov 2022 | 100 | 15,743 (0%) | 0% | 41.8 | 4,178 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2022 | 8,968 | 46,855 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.02 per share. | 02 Nov 2022 | 8,968 | 15,643 (0%) | 0% | 125.0 | 1,121,183 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 02 Nov 2022 | 8,968 | 24,611 (0%) | 0% | 41.8 | 374,683 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 02 Nov 2022 | 400 | 16,043 (0%) | 0% | 41.8 | 16,712 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2022 | 400 | 55,823 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.00 per share. | 02 Nov 2022 | 400 | 15,643 (0%) | 0% | 125 | 50,000 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 110.82 per share. | 17 Oct 2022 | 4,960 | 15,643 (0%) | 0% | 110.8 | 549,682 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 80.83 per share. | 07 Feb 2022 | 2,030 | 18,309 (0%) | 0% | 80.8 | 164,081 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 80.78 per share. | 07 Feb 2022 | 1,280 | 19,459 (0%) | 0% | 80.8 | 103,398 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 79.67 per share. | 07 Feb 2022 | 980 | 20,338 (0%) | 0% | 79.7 | 78,073 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 80.68 per share. | 07 Feb 2022 | 809 | 16,483 (0%) | 0% | 80.7 | 65,269 | Common Stock |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 62,483 | 62,483 | - | - | Stock Option | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 9,175 | 9,175 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 89.62 per share. | 16 Aug 2021 | 5,628 | 15,608 (0%) | 0% | 89.6 | 504,395 | Common Stock |